CPAC Systems and Epec Enter Collaboration Agreement to Strengthen Intelligent Control System Offerings
11.6.2025 12:00:00 EEST | Business Wire | Press release
CPAC Systems AB and Epec Oy are proud to announce a collaboration agreement rooted in a shared commitment to advancing intelligent, connected solutions in the off-highway and commercial vehicle sectors. This strategic alliance unites two leading Nordic technology companies with a common goal: to accelerate the development of scalable, integrated systems that drive innovation across the mobility landscape.
“At Epec, we are proud to join forces with CPAC Systems to deliver smarter, more sustainable control system solutions to OEMs around the world. This union is all about creating real value for our customers. By integrating our robust hardware and software platforms with CPAC Systems’ advanced system capabilities, we can accelerate the development of next-generation off-highway and commercial vehicles that are both efficient and future-ready.”
— Jyri Kylä-Kaila, CEO, Epec Oy
Combining Expertise for Next-Generation Solutions
CPAC Systems, a subsidiary of the Volvo Group, brings over two decades of experience in delivering innovative embedded systems, including autonomous vehicle platforms, electromobility solutions, and drive-by-wire technologies. Epec Oy, part of the Ponsse Group, has a strong legacy dating back to 1978 and has evolved into a leading provider of intelligent control systems, tailored electronics, and electric/hybrid vehicle technologies for the off-highway industry. With deep expertise in embedded software, connectivity, and functional safety, Epec delivers scalable solutions that support OEMs in building machines that are smarter, more efficient, and future-ready.
The collaboration agreement will enable the two companies to offer complementary solutions to OEM customers in the off-highway and commercial vehicle sectors. By aligning offerings across electronics, control systems, and system integration capabilities, CPAC Systems and Epec aim to provide customers with robust, scalable solutions, empowering operators with tools that are intuitive, intelligent, and connected.
"We are excited to collaborate with Epec to push the boundaries of intelligent control systems. Our shared ambition is to create future-ready solutions that empower OEMs to meet sustainability targets and operational demands without compromise. This alliance reflects our ongoing commitment to innovation, integration, and quality at every level."
— Marcus Wingolf, CEO, CPAC Systems AB
Shared Vision for Sustainable and Connected Mobility
Both companies share a commitment to sustainability and innovation. By leveraging their combined strengths, CPAC Systems and Epec aim to create solutions that not only meet the current demands of the industry but also pave the way for future advancements in autonomous and electric vehicle technologies.
About CPAC Systems AB
CPAC Systems AB, part of the Volvo Group, based in Gothenburg, Sweden, specializes in developing cutting-edge embedded control and automation solutions for marine, construction, agriculture, and commercial vehicle industries, focusing on areas such as electromobility, autonomous driving, and situational awareness.
www.cpacsystems.se
About Epec Oy
Epec Oy, based in Seinäjoki, Finland, is a system supplier specializing in advanced electrics and electronics for efficient, safe, and connected non-road mobile machinery and commercial vehicles. As part of the Ponsse Group, Epec has a long-standing history of providing reliable control systems and customized solutions for various applications.
www.epec.fi
View source version on businesswire.com: https://www.businesswire.com/news/home/20250611492749/en/
Contacts
Media Contacts:
CPAC Systems AB
Email: sales@cpacsystems.se
Phone: +46 (0)31-352 16 00
Epec Oy
Email: sales@epec.fi
Phone: +358 (0)20 760 8111
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom